Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J2468 · per 25 MCG

Inj, palonosetron (posfrea)

Products billed under this code include Posfrea.

Payment limit per 25 MCG, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J2468

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Posfrea Avyxa Pharma, LLC 83831-0105-01 10 $540.86

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $54.086 −$1.144 25 MCG Inj, palonosetron (posfrea) v1, posted September 17, 2026
3Q26 $55.23 −$0.059 25 MCG Inj, palonosetron (posfrea) v1, posted September 15, 2026
2Q26 $55.289 −$3.286 25 MCG Inj, palonosetron (posfrea) v1, posted September 15, 2026
1Q26 $58.575 +$0.339 25 MCG Inj, palonosetron (posfrea) v1, posted September 15, 2026
4Q25 $58.236 −$0.599 25 MCG Inj, palonosetron (posfrea) v1, posted September 8, 2026
3Q25 $58.835 −$1.07 25 MCG Inj, palonosetron (posfrea) v1, posted March 10, 2026
2Q25 $59.905 – 25 MCG Inj, palonosetron (posfrea) v1, posted March 10, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files